Skip to main content

Table 1 Clinical characteristics of the study population (N = 78) in this study

From: Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state

Characteristics All Low risk exacerbator (LRE) High risk exacerbator (HRE) PFT I PFT II
Number of patients 78 60 18 43 35
Age (years)
 Range 40–93 40–91 52–93 40–90 52–93
 Mean ± s.e.m 74.17 ± 1.446 73.63 ± 1.673 75.94 ± 2.889 72.37 ± 2.020 76.37 ± 2.025
Gender
 Male 68 (87.2%) 50 (83.3%) 18 (100%) 36 (83.7%) 32 (91.4%)
 Female 10 (12.8%) 10 (16.7%) 0 (0%) 7 (16.3%) 3 (8.6%)
FEV1 (% predicted)
 Range 24.6–97.9 30.5–97.9 24.6–73.8 50.0–97.9 24.6–49.6
 Mean ± s.e.m 53.24 ± 1.682 55.73 ± 1.902 44.95 ± 2.901 63.62 ± 1.702 40.49 ± 1.097
FEV1/FVC
 Range 37.31–69.54 45.33–69.54 37.31–66.86 52.30–69.54 37.31–69.18
 Mean ± s.e.m 59.59 ± 0.767 60.98 ± 0.783 54.95 ± 1.673 62.45 ± 0.738 56.07 ± 1.218
Current smoking
 No 17 (21.8%) 13 (21.7%) 4 (22.2%) 11 (25.6%) 6 (17.1%)
 Yes 61 (78.2%) 47 (78.3%) 14 (77.8%) 32 (74.4%) 29 (82.9%)
Medication
 LAB 31 (39.7%) 28 (46.7%) 3 (16.7%) 28 (65.1%) 3 (8.6%)
 LABA + ICS 45 (57.7%) 30 (50.0%) 15 (83.3%) 13 (30.2%) 32 (91.4%)
 No 2 (2.6%) 2 (3.3%) 0 (0%) 2 (4.7%) 0 (0%)
  1. LRE low risk exacerbator, HRE high risk exacerbator, PFT pulmonary function test, PFT I FEV1 ≥ 50, PFT II FEV1 < 50, FEV1 forced expiratory volume in the first second, FVC forced vital capacity, LAB long-acting bronchodilator, LABA long-acting β2 agonists, ICS inhaled corticosteroid